Ariel Invites Us on a Journey to Decarbonise Laundry

Ariel Invites Us on a Journey to Decarbonise Laundry

Every degree makes a difference: together we can help reduce carbon emissions

  • Ariel expands its 2030 Brand Ambition to focus on decarbonising laundry at every step – from design, manufacturing and distribution to consumer use and end of life, whilst maintaining superior cleaning performance.
  • The flagship pan-European consumer engagement campaign “Every Degree Makes a Difference”, which advocates for lower washing temperatures, is a cornerstone of the new Ambition.

GENEVA–(BUSINESS WIRE)–
Today, at the ChangeNOW online Live Talk, Procter & Gamble’s (NYSE:PG) Ariel laundry detergent brand will announce an expanded 2030 Brand Ambition focused on “reinventing clean to decarbonise laundry across its entire value chain.”

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210311005112/en/

Laundry's Carbon Footprint (Graphic: Business Wire)

Laundry’s Carbon Footprint (Graphic: Business Wire)

To do this Ariel has focused on ensuring it can deliver a superior clean in colder water, whilst also committing the brand’s voice to encourage small habit changes such as lowering wash temperatures. The brand is also working towards establishing a sustainable supply chain with industry and suppliers, as well as partnering for innovation.

The first milestone in this journey is the roll out of Ariel’s pan-European consumer engagement campaign, “Every Degree Makes a Difference” in content partnership with National Geographic Creative Works, to demonstrate that through turning down our washing cycle temperature we can together reduce greenhouse gas emissions. The campaign, which is already launched in Germany and is coming to France this week, seeks to achieve a five degree drop in average wash temperatures in Europe by 2025.

Ariel’s Life Cycle Assessment (LCA) found that on average in Europe 60% of the environmental footprint of laundry comes when the product is being used, mainly from the energy used to heat the water. Lowering the wash temperature is the single most important thing we can all do to reduce the environmental impact of laundry. Through short films and emotive images created by National Geographic Creative Works, the campaign highlights the impact of global warming on the arctic regions and brings to life that we can all make an impact on our planet.

As part of its 2030 Ambition, Ariel is pursuing a sustainable supply chain through analysing the ingredients with highest CO2 potential in its formula and exploring alternative sourcing, working closely with its suppliers. The brand is looking into partnerships to find new solutions that help further decarbonise its value chain, including novel sources of carbon and new models for recycling.

“Serving five billion people gives our brands the unique opportunity to promote conversations, influence attitudes and change behaviour,” comments Virginie Helias, Chief Sustainability Officer at Procter & Gamble. “Ariel cleans impeccably in cold water and enables us to switch down the wash temperature when doing the laundry. With this we can all unite on the journey to decarbonise laundry across the entire value chain, helping the climate without compromising on cleaning performance.”

Ariel’s core purpose is to reinvent clean to drive progress, and its expanded Ambition announced today is underpinned by a wide range of other actions it is taking to ensure the interconnected sustainability challenges we all face are being addressed. These include circular packaging, responsibly sourced and less carbon intensive ingredients, and establishing an even more efficient supply chain among others. On the societal side, Ariel continues to advocate how laundry is not only a woman’s job, but the responsibility of everyone in the household.

Ariel is one of P&G’s leading brands, and the Brand Ambition announcement is part of the overall commitment from P&G for 100% of their leadership brands to enable and inspire responsible consumption by 2030 as part of the company’s Ambition 2030 sustainability goals.

To access images and other multimedia content, please visit here.

About Every Degree Makes a Difference Campaign

“Every Degree Makes a Difference” is a campaign being run by Ariel that aims to educate consumers on the benefits of turning their washing machines down and doing their laundry at lower temperatures. The campaign has been designed to educate consumers on the following key information: https://www.nationalgeographic.com/ariel-every-degree-makes-a-difference/

The Life Cycle Assessment of a fabric care detergent clearly signifies that the environmental footprint is only 40% product related versus up to 60% usage related at home when people use the washing machine (50% from heating the water, data is based on the average for European region).

About Procter & Gamble

P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit https://www.pg.com/ for the latest news and information about P&G and its brands.

Rosie Abrahamson

Senior Account Executive

+44 (0) 7961577369

[email protected]

KEYWORDS: Switzerland Europe

INDUSTRY KEYWORDS: Retail Home Goods Other Retail Environment

MEDIA:

Logo
Logo
Photo
Photo
Laundry’s Carbon Footprint (Graphic: Business Wire)

CytoDyn’s Long-Haulers COVID-19 Trial Enrolled 20 Patients Within 10 Days; Enrollment to be Completed This Month

VANCOUVER, Washington, March 11, 2021 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today 20 patients have been enrolled and dosed in the first 10 days of its Phase 2 trial for COVID-19 long-haulers symptoms. The trial is designed to enroll 50 patients.

In summary, each patient will receive eight weekly doses followed by four weeks of safety evaluation. The endpoint measure will be at Day 56 with the trial data expected by mid-summer of 2021.

This trial is a Phase 2, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of leronlimab in patients experiencing prolonged coronavirus disease 2019 (COVID-19) symptoms (long-haulers).

Christopher Recknor, M.D., Vice President, Clinical Development, noted, “This trial represents a potential solution for many patients with post-acute sequalae from COVID-19 (PASC) known as long-haulers where currently no treatment is available. Patients in the trial have had lingering symptoms for over 12 weeks and they need help. We are looking at sophisticated biomarkers that will help us identify who benefits and why. This group of afflicted patients may represent a signal for all those who have had other post-viral complications and have lost their quality of life since the virus. It is of interest that patients with chronic fatigue present with similar complaints as those with PASC. In our CD10 COVID mild-to-moderate trial with leronlimab, we noted a reduction in adverse events or symptoms including fatigue, diarrhea, chest pain, fatigue, muscle weakness, and anxiety in treated vs. placebo groups. Since the CD10 trial did not have a restriction on the time from diagnosis of when COVID was made, some patients were post-COVID several weeks and may have been in the initial stages of PASC. Our job is to use what we learned from prior trials and show that Vyrologix™ can help.”

Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, commented, “We are pleased to initiate this much awaited trial. Our NASH trial has similarly enrolled 20 patients and is moving forward with rapid speed thanks to Dr. Chris Recknor, who is in charge of both programs. With strong CD12 results, NASH and long-hauler results not too far away, along with our BLA submission for HIV coming up, we are more confident than ever about the future of leronlimab for many indications. We are also equally very excited about our cancer trial and ready to file for a Breakthrough Therapy Designation meeting with the FDA this month.”

Enrollment continues in the Phase 2 clinical trial for COVID-19 long-haulers in several hospitals and clinics throughout the U.S., which are identified on the Company’s website at www.cytodyn.com under the “Clinical Trial Enrollment” section of the homepage. Center for Advanced Research & Education, LLC, owned by Dr. Recknor, is one of the clinical locations for the Company’s Phase 2 trial. Dr. Recknor is not involved in trial operations or in recruiting patients for this trial at this site. The agreement with the Center for Advanced Research & Education was negotiated in the ordinary course of business and on terms that are comparable to the terms available to unrelated third parties.   

About COVID-19 Long-Hauler Symptoms

According to a recent article from The Journal of the American Medical Association and a study done by British scientists, researchers estimate about 10% of COVID-19 patients become long-haulers. Published studies and surveys conducted by patient groups indicate 50% to 80% of patients continue to have troublesome symptoms three months after the onset of COVID-19 — even after tests no longer detect virus in their body. The list of long-hauler symptoms is extensive and inconsistent. For some people, the lingering symptoms are nothing like the original symptoms when they were first infected with COVID-19. The most common long-hauler symptoms include: coughing, ongoing, sometimes debilitating, fatigue, body aches, joint pain, heart issues, shortness of breath, loss of taste and smell, difficulty sleeping, headaches and brain fog (cognitive impairment).

About Leronlimab (PRO 140)

The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for critical illnesses. The first indication is a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH. Leronlimab has completed 11 clinical trials in over 1,200 people and met its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients). 

In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use. 

In the setting of cancer, research has shown that CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is, therefore, conducting a Phase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation by the FDA in May 2019.  

The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation. It may be crucial in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn was conducting a Phase 2 clinical study with leronlimab to support further the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD, blocking the CCR5 receptor from recognizing specific immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA granted orphan drug designation to leronlimab for the prevention of GvHD. Due to the lack of patients during the COVID-19 pandemic, the Company suspended its Phase 2 trial for acute GvHD. 

About CytoDyn

CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a critical role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and immune-mediated illnesses, such as GvHD and NASH.

CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients. CytoDyn has been working diligently to refile its Biologics License Application (“BLA”) for this HIV combination therapy since receiving a Refusal to File in July 2020 and subsequently meeting with the FDA telephonically to address their written guidance concerning the filing. CytoDyn expects to refile its BLA in the first half of calendar year 2021.

CytoDyn has completed a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab monotherapy indication. If successful, it could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV. No drug-related serious site injection reactions reported in about 800 patients treated with leronlimab and no drug-related SAEs reported in patients treated with 700 mg dose of leronlimab. Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than six years.

CytoDyn is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is at www.cytodyn.com

Forward-Looking Statements 

This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict.  Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as “believes,” “hopes,” “intends,” “estimates,” “expects,” “projects,” “plans,” “anticipates” and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Forward-looking statements specifically include statements about leronlimab, its ability to provide positive health outcomes, the possible results of clinical trials, studies or other programs or ability to continue those programs, the ability to obtain regulatory approval for commercial sales, and the market for actual commercial sales. The Company’s forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i) the sufficiency of the Company’s cash position, (ii) the Company’s ability to raise additional capital to fund its operations, (iii) the Company’s ability to meet its debt obligations, if any, (iv) the Company’s ability to enter into partnership or licensing arrangements with third parties, (v) the Company’s ability to identify patients to enroll in its clinical trials in a timely fashion, (vi) the Company’s ability to achieve approval of a marketable product, (vii) the design, implementation and conduct of the Company’s clinical trials, (viii) the results of the Company’s clinical trials, including the possibility of unfavorable clinical trial results, (ix) the market for, and marketability of, any product that is approved, (x) the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Company’s products, (xi) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii) general economic and business conditions, (xiii) changes in foreign, political, and social conditions, and (xiv) various other matters, many of which are beyond the Company’s control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release.

CONTACTS

Investors:

Michael Mulholland
Office: 360.980.8524, ext. 102
[email protected]

 



REPLY: A New Push for Digitalization in the Food and Beverage Industry

REPLY: A New Push for Digitalization in the Food and Beverage Industry

TURIN, Italy–(BUSINESS WIRE)–
Reply’s report, conducted with the trend platform SONAR, examines the impact of the pandemic on the Food and Beverage (F&B) Industry. COVID-19, as a catalyst for digitalisation, offers opportunities to create new business models in Europe.

Across Europe, interest in online delivery services grew by an average of 140 per cent in 2020. The average share price for the largest delivery service aggregators increased by 53 per cent. On average, 34 per cent of Europeans ordered food online in the third quarter of 2020, compared to 56 per cent globally.

In the early stages of the pandemic, F&B outlets across Europe were closed. With an increase in online grocery shopping, new demands on grocery retailers’ logistics are emerging. Digital logistics at the backend of supply chains is important to provide a more comprehensive choice of products to consumers. Providing an omnichannel approach for the customer journey – from first contact to delivery – will be key in reaching diverse consumers with various needs.

Food delivery services stepped in to fill the gap left by the lockdown restrictions for restaurants, bars, cafés and other venues. Until restaurants open long-term, a blending of online and offline experiences will be necessary to retain and delight customers through personalized offers. Digital reservation tools will grow in importance and online seat reservations are in demand for when restrictions are lifted.

Mass market F&B chains have offered mobile and app-first offers, discounts, ordering and payment functionality for some time now. Pre-order, meal kits or post payment loyalty: more and more of the F&B industry will need to function online. According to the European Central Bank, 87% of Europeans say they will continue to pay with cash less frequently. F&B outlets that use technology for analysis and decision-making will reap the rewards. Efficiency in areas such as menu planning for restaurants as well as food ordering for consumers should be maximised. Digitally capturing consumer data will help grocery retailers better understand consumers and differentiate themselves from the competition.

“F&B companies that design the end-to-end consumer experiences based on strategic, data-driven insights create opportunities for hyper-personalised offers tailored to custom-made preferences, which not only contributes to additional revenue streams, but also consumer loyalty. Understanding consumer behaviour and preferences provides an assured perspective on how brands can grow in the long term”, comments Filippo Rizzante, CTO Reply.

The COVID-19 Food & Beverage report is part of a series published by Reply on how the pandemic is impacting businesses and daily lives. All reports can be found at Reply COVID-19 series.

To read the full report, please click here.

Reply

Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com

Reply

Fabio Zappelli

[email protected]

Tel. +390117711594

Aaron Miani

[email protected]

Tel. +44 (0)20 7730 6000

KEYWORDS: Europe United States Italy North America

INDUSTRY KEYWORDS: Technology Other Retail Supermarket Software Restaurant/Bar Food/Beverage Internet Data Management Retail Online Retail

MEDIA:

Logo
Logo

Notice of Annual General Meeting of Husqvarna AB (publ)

PR Newswire

STOCKHOLM, March 11, 2021 /PRNewswire/ — The shareholders of Husqvarna AB (publ) are hereby invited to participate in the 2021 Annual General Meeting (“AGM”), which will be held on Wednesday, April 14, 2021. Due to the Covid-19 pandemic, the AGM will be conducted pursuant to so called mail-in procedures, meaning that no shareholders will attend the AGM in person or through proxy. Instead, shareholders can participate in the AGM by voting and submitting questions in advance pursuant to the instructions described below.

In order to participate in the AGM, a shareholder must   

a. be registered in the register of shareholders maintained by Euroclear Sweden AB as of Tuesday, April 6, 2021, and            

b. notify attendance at the AGM no later than Tuesday, April 13, 2021. The exercise of voting rights in accordance with the mail-in procedure will be considered as a notification from the shareholder to attend the meeting.

Shareholders whose shares are registered in the names of banks or other nominees must temporarily register the shares in their own name in order to be entitled to participate in the AGM via the mail-in process not later than on Thursday, April 8, 2021. To ensure that such registration is in place as of Thursday, April 8, 2021, shareholders must inform the nominee well in advance of that date. 


A. Overview of Mail-In Procedures for the


 


AGM


 

Due to the Covid-19 pandemic and in order to ensure the health and safety of the Company’s shareholders, employees and other stakeholders, the Board of Directors of Husqvarna AB has resolved on extraordinary meeting procedures pursuant to Section 22 of the temporary act on general meetings (2020:198) (the “Temporary Act. Specifically, the following procedures will apply:

    1. The AGM will take place on Wednesday, April 14, 2021. However, no shareholders, proxy holders or other external persons will be able to attend in person.
    2. Shareholders will only be able to participate in the AGM by voting on the matters and the proposals on the meeting agenda and submitting questions to the Company in advance. See Section B, below, for more details on how.
    3. The Agenda for the AGM is as set forth below in Section C, with certain items being further explained in Section D.
    4. A press release will be issued following the AGM informing of those material items that are approved by the AGM as soon as the outcome of the mail-in voting procedure has been finally established. Details of the actual voting results will be included in the minutes of the meeting and will be published within two weeks thereafter.
    5. While not technically part of the AGM, we note that a pre-recorded presentation of the year 2020 by the President and CEO (“CEO”) and the Chair of our Board (the “Chair”) will be available on Husqvarna Group’s website, www.husqvarnagroup.com, on April 14, 2021. In that presentation, questions submitted in connection with the AGM may be addressed. 

At the time of the issue of this Notice of AGM, the total number of shares in the Company amounts to 111,688,331 A-shares and 464,655,447 B-shares, corresponding to 158,153,875.7 votes in total. The Company holds no A-shares or B-shares as of the date of this notice.  

B. Process for Advanced Voting and Questions 

A shareholder can exercise his/her/its shareholder’s rights at the AGM by in advance (A) voting on the items on the agenda of the AGM, and (B) submitting questions to the Company.

Any registered shareholder intending to participate in the AGM (via advanced voting or questions), must submit the following information in connection with their respective submissions:

  • the shareholder’s name,
  • personal or organization number,
  • postal address,
  • email address, and
  • telephone number.

The data received will be computerized and used solely for the purpose of the 2021 AGM. 

For shareholders wishing to participate through an authorized representative (i.e., where such authorized representative is the one submitting advanced voting or questions on behalf of such shareholder), the Company will provide power of attorney templates on the Company’s website. Shareholders participating through an authorized representative must submit the power of attorney together with the voting form or question. If the shareholder is a legal entity, a copy of a registration certificate or a corresponding document for the legal entity shall be enclosed.

B1. Advance voting 

Advance voting will be available as of Thursday, March 11, 2021 until Tuesday, April 13, 2021. A shareholder can vote in advance by any of the following three methods:

1.  Website Voting: Voting may be done electronically through signing with BankID on the Company’s website www.husqvarnagroup.com

2.  Email Voting: Voting may be submitted by completing the advance voting form available on the Company’s website www.husqvarnagroup.com and then emailing such form to the following email address [email protected], together with any power of attorney and/or other authorization documents (See Section B, above).

3.  Regular Mail: Voting may be submitted by completing the advance voting form available on the Company’s website www.husqvarnagroup.com and after completion sending a physical copy (i.e., printed out) of such form, together with any power of attorney and/or other authorization documents (See Section B, above) to the following address, Husqvarna AB (publ), “Advance voting 2021 AGM”, c/o Euroclear Sweden AB, P.O. Box 191, SE-101 23 Stockholm, Sweden.

A shareholder cannot give any other instructions than selecting one of the options specified at each point in the advanced voting form. A vote (i.e., the postal voting in its entirety) is invalid if the shareholder has modified the form to provide specific instructions or conditions or if pre-printed text is amended or supplemented.

An email or regular mail voting form, together with any enclosed power of attorney and other authorization documentation, must have been received by Husqvarna no later than on Tuesday, April 13, 2021. If received later, the vote will be disregarded.

For questions regarding advance voting, please contact Euroclear Sweden AB,

ph.+46 36 14 70 10, between 9:00 a.m. and 4:00 p.m. (CET) weekdays. 

B2. Questions 

Questions to the Company in connection with the AGM can be submitted to Husqvarna up until Sunday, April 4, 2021. Shareholders wishing to pose questions may do so by any of the following methods:  

1.  Email: Questions may be submitted by emailing to the following email address [email protected].  

2.  Regular Mail: Questions may be submitted by regular mail to the following address, Husqvarna AB, “AGM 2021”, P.O. Box 7454, SE-103 92 Stockholm, Sweden.

In order for questions so submitted to be accepted, such submission must include the name of the shareholder, including such shareholder’s personal or organization number. While not formally required, we also ask that all submission include the submitting shareholder’s postal address, email address and telephone number.  

Questions submitted by shareholders must have been received by Husqvarna no later than on Sunday, April 4, 2021, and will be responded to and published not later than on Friday, April 9, 2021. The questions and responses will be available at the Company, Husqvarna AB, Regeringsgatan 28, SE-111 53 Stockholm, Sweden and on the Company’s website, www.husqvarnagroup.com, and will be sent to the shareholder provided the shareholder’s address is known by the Company or provided by the shareholder together with the question.

The Board of Directors and the CEO shall, upon request of a shareholder, and provided that the Board of Directors deems this can be done without causing major harm to the Company, inform about matters which might affect the assessment of an item on the agenda or circumstances affecting Husqvarna’s or its subsidiaries’ financial situation or about Husqvarna’s relation to another Group entity, or in relation to the consolidated Annual Report

C. AGM Agenda

1. Opening of the AGM

2. Election of Chair of the Meeting

3. Preparation and approval of the voting list

4. Approval of the agenda

5. Election of one or two minute-checkers

6. Determination as to whether the Meeting has been duly convened

7. Resolutions concerning

a. adoption of the Profit and Loss Statement and the Balance Sheet as well as the Consolidated Profit and Loss Statement and the Consolidated Balance Sheet

b. proposed distribution of earnings (allocation of the Company’s profit or loss pursuant to the adopted Balance Sheet)

c. discharge from liability of the Directors and the CEO

8. Determination of the number of Directors and Auditors to be elected      

a. number of Directors

b. number of Auditors  

9. Determination of remuneration to the Directors

10. Election of Directors and Chair of the Board      

a. individual election of Directors

b. election of Chair of the Board

11.Election of, and remuneration to, external Auditors                  

a. election of external Auditors                  

b. determination of remuneration to external Auditors

12. Resolution to approve the Remuneration Report

13. Resolution on remuneration guidelines for Group Management 

14. Resolution regarding the adoption of a long-term incentive program (LTI 2021)

15. Resolution on authorization to enter into equity swap arrangements to cover obligations under LTI 2021 and any previously resolved LTI programs

16. Resolution on authorization to resolve on the issuance of new shares

17. Resolution to amend the Articles of Association

18. Closing of the Meeting

D. Explanation of Certain AGM Proposals 


Election of Chair of the Meeting (item 2) 

The Nomination Committee proposes that Björn Kristiansson be elected Chair of the AGM. 


Preparation and approval of the voting list (item 3)

The voting list that is proposed to be approved is the voting list that has been prepared by Euroclear Sweden AB, based on the general meeting share register and votes received, checked by the minute-checkers.


Election of one or two minute-checkers (item 5)

The Board of Directors proposes that two minute-checkers be elected, and that Henrik Didner, Didner & Gerge Fonder AB and Ricard Wennerklint, If Skadeförsäkring AB are elected, or, if someone or both of them are unable to attend the meeting, any other person proposed by Husqvarna’s Nomination Committee.


Proposed distribution of earnings (item 7 b)

The Board of Directors proposes a dividend for financial year 2020 of SEK 2.40 per share, to be paid in two installments, firstly SEK 0.80 per share with Friday, April 16, 2021 as the first record day, and secondly SEK 1.60 per share with Monday, October 18, 2021 as the second record day. Assuming the AGM resolves in accordance with the Board of Directors’ proposal, the estimated (i) last day for trading in Husqvarna shares with right to the applicable part of the dividend payment (ii) applicable record day, and (iii) date for payment from Euroclear Sweden AB for each of the installments are as follows:

First Installment

                                    (SEK 0.80 per share)

Second Installment

                                    (SEK 1.60 per share)

Last day for trading

April 14, 2021 (Wednesday)

October 14, 2021 (Thursday)

Record Day

April 16, 2021 (Friday)

October 18, 2021 (Monday)

Payment Date

April 21, 2021 (Wednesday)

October 21, 2021 (Thursday)



Determination of the number of Directors and Auditors to be elected (item 8)

The Nomination Committee proposes that the Board of Directors shall be comprised of eight Directors to be elected by the AGM and one audit firm.


Determination of remuneration to the Directors (item 9)

The Nomination Committee proposes that Directors elected by the AGM and not employed by the Company receive the following basic compensation for their board work in 2021 (plus applicable additional remuneration for committee work):

 Proposal

                                    2021


2020


Percentage Increase

Chair of the Board

SEK 2,075,000 

SEK 2,000,000

3.8%

Director

SEK    600,000  

SEK     580,000

3.4%

Audit Committee Chair

SEK    275,000

SEK     240,000

14.6%

Audit Committee member 

SEK    175,000

SEK     135,000

29.6%

People & Sustainability Committee Chair

SEK    145,000

SEK     140,000

3.6%

People & Sustainability Committee member 

SEK      85,000

SEK       80,000

6.3%

In addition to the compensation described above, and reimbursement for travel expenses, the Nomination Committee proposes that the following compensation be paid to elected Directors for each physical meeting attended in Sweden (no change from prior year):

Residence of Director

Per Meeting Compensation

Nordic Countries

None

Europe (non-Nordic)

                  SEK 10,000

Outside of Europe

USD   3,500

The Nomination Committee declares its expectation that each elected Director engage themselves financially in Husqvarna by acquiring Husqvarna shares within a period of five years, corresponding to approximately one year’s remuneration, calculated before tax.


Election of Directors and Chair of the Board (item 10)


a) Individual election of Directors

Due to Ulla Litzén giving notice to the Nomination Committee that she will not be available for re-election as a Board member, the Nomination Committee proposes that Ingrid Bonde be elected as a new Board member at the 2021 AGM and that all other current members be re-elected. Thus, the Nomination Committee proposes the election of:

1.  Tom Johnstone, 

2.  Katarina Martinson, 

3.  Bertrand Neuschwander,

4.  Daniel Nodhäll, 

5.  Lars Pettersson, 

6.  Christine Robins,

7.  Henric Andersson, and

8.  Ingrid Bonde (new election).

The proposed Directors are presented in more detail on the Company’s website.


b) Election of Chair of the Board

The Nomination Committee proposes that Tom Johnstone be appointed Chair of the Board. 


Election of, and remuneration to, external Auditors (item 11)


a) Election of external Auditors

The Nomination Committee proposes, in accordance with the Audit Committee recommendation after having conducted a formal tender process, the election of KPMG as external Auditor for the period from the 2021 AGM up until the end of the 2022 AGM. 

KPMG has informed that, provided that the AGM adopts the Nomination Committee’s proposal regarding election of external Auditors, the registered auditor-in charge will be authorized public accountant Joakim Thilstedt.

Neither the Nomination Committee proposal nor the Audit Committee recommendation of external Auditors has been subject to influence from third-party or have been forced by any terms and conditions that has limited the freedom of choice in the election of external Auditors.


b) Determination of remuneration to external Auditors

The Nomination Committee proposes that the external Auditors’ fee shall be paid on the basis of approved invoice.


Resolution on remuneration guidelines for Group Management (item 13)

The Board of Directors proposes that the following remuneration guidelines, for the CEO and other members of Group Management, should be approved by the 2021 AGM.

These guidelines do not apply to any remuneration otherwise decided or directly approved by the AGM or other general meeting.

The overarching ambition of the Company’s strategy is market leadership, of which long-term profitable growth and being an innovation leader are important aspects.

Built on a strategy for market leadership, the Company’s business model is designed for profitable growth, bringing the best forestry, lawn and garden and construction solutions to the market by maximizing assets and minimizing waste and carbon dioxide from operations. Further information on the Company’s strategy and financial targets can be found on the Company’s website http://www.husqvarnagroup.com/en/financial-targets.

A prerequisite for the successful implementation of the Company’s business strategy and safeguarding of its long-term interests, including its sustainability, is that the Company is able to recruit and retain qualified personnel. To this end, it is necessary that the Company offers competitive remuneration.

The guidelines set forth in this item shall apply to remuneration and other employment conditions of Group Management, as defined in the Company’s Annual Report. The guidelines shall apply to contracts of employment entered into after the 2021 AGM and also to amendments made thereafter to contracts of employment which are in force. 

Remuneration to members of Group Management shall be on market terms and based on the position held, individual performance and Group performance, and shall be on a competitive basis in the country of employment. The overall remuneration package for Group Management is comprised of fixed cash salary, variable cash remuneration in the form of short-term incentives based on annual performance targets, long-term incentives, pension and other benefits. In addition, there are conditions on notice of termination and severance pay.

Additionally, the general meeting may – irrespective of the guidelines – resolve on, among other things, share-related or share price-related remuneration.

The Company shall aim to offer a competitive total remuneration (i.e., all remuneration elements described below) level with a primary focus on “pay for performance”.

Fixed cash salary

Fixed salary shall constitute the basis for total remuneration and may amount to not more than 70% of the total remuneration. The salary shall be related to the relevant market and shall reflect the degree of impact, contribution and knowledge involved in the position. The salary levels shall be reviewed regularly (normally annually) in order to ensure continued competitiveness and reward performance.

Variable cash remuneration (Short-term Incentive, “STI”)

The satisfaction of criteria for awarding variable cash remuneration shall be measured over a period of one year. The variable cash remuneration may amount to not more than 150% of the fixed salary and not more than 50% of the total remuneration. The Board of Directors decides whether the maximum levels shall be utilized or if a lower level shall be used. The level of STI is set by the Board of Directors based on size of position, taking into account degree of impact, contribution and knowledge involved in the position but also country of employment.

Variable cash remuneration shall be conditional upon the fulfilment of defined financial criteria – such as operating income, sales growth, operating working capital etc., as well as non-financial criteria, to promote the Group’s business strategy including its sustainability. The Board of Directors and the People & Sustainability Committee shall establish these criteria for the Group and/or for the business unit for which the member of Group Management is responsible and define the minimum/entry level, which must be exceeded for variable remuneration to be paid, and a maximum/stretch level relevant for the upcoming measurement period.

Up to a maximum of 20% of the CEO’s and other Group Management member’s total STI opportunity may be based on financial or non-financial individual key performance indicators (KPIs). The criteria shall be designed so as to contribute to the Company’s business strategy and long-term interests, including its sustainability. The extent to which the criteria for awarding variable remuneration has been satisfied shall be evaluated/determined when the applicable one-year measurement period has ended. The People & Sustainability Committee is responsible for the evaluation and it shall be based on the latest financial information made public by the Company. Any individual KPIs for the CEO shall be determined and evaluated by the Board of Directors and the People & Sustainability Committee while the CEO shall be responsible for determining and evaluating individual KPIs for other members of Group Management.

Long-term incentive

The Board of Directors will annually evaluate if a long-term incentive program should be offered and be proposed to the AGM. The award level of such long-term incentive program may amount to not more than 120% of the fixed salary when the program is launched.

Pension and other benefits

Pension and disability benefits shall be designed to reflect regulations and practice in the country of employment. Pension plans shall be defined contribution plans and the employer contribution, including contributions for disability pension/insurance, may amount to not more than 40% of the fixed cash salary and not more than 30% of the total remuneration.

Other benefits may include, for example, life and health care insurance, housing allowance and company cars. Costs relating to such benefits may amount to not more than 20% of the fixed cash salary and not more than 15% of the total remuneration. For employments governed by mandatory rules, pension and other benefits may be duly adjusted for compliance with mandatory rules or established local practice, taking into account, to the extent possible, the overall purpose of these guidelines.

Group Management members who are expatriates may receive additional remuneration and benefits to the extent reasonable in light of the special circumstances associated with the expatriate arrangement, taking into account, to the extent possible, the overall purpose of these guidelines. Such remuneration and benefits may not in total exceed 80% of the fixed cash salary.

Termination of employment

The notice period may not exceed twelve months if notice of termination of employment is made by the Company. Fixed cash salary during the period of notice and severance pay may together not exceed an amount equivalent to fixed salary for two years. The period of notice may not exceed six months when termination is made by the Group Management member, unless there is a right to severance pay to compensate for a longer notice period. Members of Group Management shall be obliged not to compete with the Company during the notice period. Based on the circumstances in each case, a non-compete obligation with continued severance pay may be applied also after the end of the notice period. Non-compete obligation shall not apply for more than 24 months from the end of the notice period and the severance pay during such non-compete period may not exceed an amount equivalent to the fixed salary.

Additionally, remuneration may be paid for non-compete undertakings to compensate for loss of income and shall only be paid in so far as the previously employed Group Management member is not entitled to severance pay. The remuneration shall amount to not more than 60% of the fixed salary at the time of termination of employment, unless otherwise provided by mandatory collective agreement provisions, and be paid during the time the non-compete undertaking applies, however not for more than 24 months following termination of employment.

Salary and employment conditions for employees

In the preparation of the Board of Directors’ proposal for these remuneration guidelines, salary and employment conditions for employees of the Company have been taken into account by including information on the employees’ total income, the components of the remuneration and increase and growth rate over time, in the People & Sustainability Committee’s and the Board of Directors’ basis of decision when evaluating whether the guidelines and the limitations set out herein are reasonable. The development of the gap between the remuneration to executives and remuneration to other employees will be disclosed in the remuneration report to be published in accordance with the EU Shareholder Rights Directive.

The decision-making process to determine, review and implement the guidelines

The Board of Directors has established a People & Sustainability Committee, which qualifies as a “remuneration committee” within the meaning of the Swedish Code of Corporate Governance (the “Committee”). The Committee’s tasks include preparing the Board of Directors’ decision to propose guidelines for Group Management remuneration. The Board of Directors shall prepare a proposal for new guidelines at least every fourth year and submit it to the general meeting. The guidelines shall be in force until new guidelines are adopted by the general meeting. The People & Sustainability Committee shall also monitor and evaluate programs for variable remuneration for Group Management, the application of the guidelines for Group Management remuneration as well as the current remuneration structures and compensation levels in the Company.

The members of the People & Sustainability Committee are independent of the Company and its Group Management. The CEO and other members of Group Management do not participate in the Board of Directors’ processing of and resolutions regarding remuneration-related matters in so far as they are affected by such matters.

Derogation from the guidelines

The Board of Directors may resolve to derogate from the guidelines, in whole or in part, if in a specific case there is special cause for the derogation and a derogation is necessary to serve the Company’s long-term interests, including its sustainability, or to ensure the Company’s financial viability. As set out above, the People & Sustainability Committee’s tasks include preparing the Board of Directors’ resolutions in remuneration-related matters. This includes any resolutions to derogate from the guidelines. Any derogation from the guidelines must not cause any of the remuneration elements to exceed two times the maximum level specified in these guidelines.


Resolution regarding the adoption of a long-term incentive program (LTI 2021) (item 14) 

Summary of the program

The Board of Directors proposes that the 2021 AGM resolves to adopt a performance based long term incentive program (“LTI 2021”) in line with the following description.

The program is based on the same principles as the incentive program granted in 2020 (LTI 2020). 

LTI 2021 is proposed to be offered to a maximum of 100 senior managers within the Husqvarna Group and offers participants the opportunity to receive “performance share awards”. Subject to the fulfilment of certain performance targets and conditions during a three-year vesting period, performance share awards to be granted in 2021 will vest and give right to Husqvarna B-shares in accordance with the following. 

Participants in LTI 2021 will be granted a number of performance share awards based on such participant’s annual target income (fixed salary plus variable salary at a target level) in 2021. 

The number of performance share awards that vest and give rights to receive B-shares further depends on the fulfilment of certain levels of increase of the Company’s value creation (defined as Earnings Before Interest and Tax – Average Net Assets x Weighted Average Cost of Capital), during the calendar years 2021-2023, as determined by the Board of Directors. These levels are “Entry”, “Target” and “Stretch”. Entry constitutes a minimum level which must be exceeded in order for the performance share awards to vest and give right to B-shares. The levels correspond to the following number of B-shares, with a linear progression between each level:

  • Entry: 10% of annual target income / the share price SEK 104.481
  • Target: 33% of annual target income / the share price SEK 104.481
  • Stretch: 66% of annual target income / the share price SEK 104.481   

If the price for the B-shares would increase more than 200% during the three-year vesting period, the number of performance share awards that vest and give right to B-shares will be limited to the value of the maximum allocation at Stretch level at a share price increase of 200% from grant of share awards to vesting (vesting period). This limitation enables control and predictability over the maximum scope and cost of the program.

Additional terms & conditions 

The performance share awards shall be governed by the following terms and conditions:

  • Shares are allotted free of charge
  • Are vested three years after grant (vesting period)
  • Vesting of performance share awards and allotment of B-shares in Husqvarna requires that the participant is then, with certain exceptions, still employed by the Husqvarna Group 
  • Carry no right to compensation for dividends on underlying shares
  • Are non-transferable

Design and administration

The Board of Directors, or a committee established by the Board, shall be responsible for the detailed design and administration of LTI 2021, in accordance with the presented terms and guidelines. To this end, the Board of Directors shall be entitled to make adjustments to meet domestic or foreign regulations or market conditions. The Board of Directors may also make other adjustments if significant changes in the Husqvarna Group, or its environment, would result in the resolved terms and conditions for LTI 2021 no longer being appropriate to apply.

Allotment

In accordance with the above principles and assumptions, LTI 2021 will comprise the following number of B-shares for the different categories of participants: the CEO, approximately 88,000 B-shares, other members of Group Management, each approximately an average of 31,000 B-shares, corresponding to a total of approximately 248,000 B- shares, and other participants, each approximately an average of 15,000 B- shares, corresponding to a total of approximately 1,365,000 B-shares. The above stated numbers are calculated assuming the attainment of performance level Stretch as described above.

Scope and costs of LTI 2021

LTI 2021 is estimated to comprise a maximum of 1.7 million B-shares, which corresponds to less than 0.3% of the total number of outstanding shares. The Company has approximately 576 million shares outstanding. The issued and outstanding rights to shares in accordance with the Company’s previous outstanding incentive programs (LTI 2018, LTI 2019 and LTI 2020) correspond to approximately 0.9% of the total number of outstanding shares. The Company’s incentive programs’ effect on important key figures is only marginal. Information on LTI 2018, LTI 2019 and LTI 2020 can be found in the Annual Report for 2020, note 4, and on the Company’s website, www.husqvarnagroup.com

LTI 2021 will be accounted for in accordance with IFRS 2 – Share-based Payment. IFRS 2 stipulates that the performance share awards should be expensed as personnel costs over the vesting period and will be reported directly against equity. Estimated social security charges will be recorded as a personnel expense in the income statement by current reservations. The cost for LTI 2021 is estimated to amount to SEK 88m before tax, if the performance level Target is reached, and is allocated over the years 2021-2024. The corresponding cost at performance level Stretch is estimated to SEK 176m. Financing costs and social security charges are included in the estimated amounts. The estimation of cost above is based on the assumptions that the share price is SEK 105 at the time of grant of the performance share awards, that the annual share price increase for the Company’s

B-shares is 5%, that social security charges amount to 25% and that the annual employee turnover is 5% among the participants of LTI 2021. In order to ensure delivery of Husqvarna B-shares under LTI 2021 and to limit the costs, including social security charges, for LTI 2021, the Board of Directors will adopt hedging measures, such as equity swap agreements with third parties, under which the third party would in its own name buy and transfer Husqvarna B-shares to the participants in accordance with LTI 2021 provided that the AGM resolves in accordance with Item 15 on the agenda. The hedging options are described below under Item 16 of the agenda. The intention is to not issue new shares as a result of LTI 2021.

The rationale for the proposal

The purpose of LTI 2021 is to influence and award long term performance, align shareholders’ and managements’ interest, attract and retain key employees and provide variable remuneration instead of fixed salary. In light of the above, the Board of Directors believes that adopting LTI 2021 will have a positive effect on the development of the Husqvarna Group and consequently that it will be beneficial to both the shareholders and the Company.

Preparation

LTI 2021 is based on the same principles as LTI 2020 and has in accordance with guidelines set out by the People & Sustainability Committee been prepared by Group Management in consultation with external advisors, taking into consideration evaluations of previous incentive programs. LTI 2021 has been reviewed at meetings of the Board of Directors in 2020 and 2021.

Resolution on authorization to enter into equity swap arrangements to cover obligations under LTI 2021 and any previously resolved LTI programs (item 15)

The Board of Directors proposes that the 2021 AGM authorizes the Board of Directors to pass a resolution, on one or more occasions, for the period up until the next AGM, to direct the Company to enter one or more equity swap agreements with a third party (e.g., a bank), on terms and conditions in accordance with market practice, to hedge the obligations of the Company under LTI 2021 and any previously resolved incentive programs (the “Covered Programs“). Under such equity swap arrangements, in exchange for certain fees paid by the Company, the third party acquires (in its own name) such number of Husqvarna B-shares as are necessary to cover the Company’s obligations under the Covered Programs and then, transfer (in its own name) such shares to the participants per the terms of the Covered Programs.

Resolution on authorization to resolve on the issuance of new shares (item 16)

The Board of Directors proposes that the 2021 AGM authorizes the Board to resolve to issue not more than 57,634,377 B-shares, which represents 10% of the total number of shares in the Company, against payment in kind, on one or several occasions, during the period until the next AGM. 

The price for the new shares shall be based on the market price of the Company’s B-shares. The purpose of the authorization is to facilitate acquisitions where the consideration will be paid with own shares.

Resolution to amend the Articles of Association (item 17)

The Board of Directors proposes that Company’s Articles of Association be amended as follows:

Present wording

New Wording

Article 13

Article 13

The Board of Directors may collect proxies in accordance with the procedure described in Chapter 7, section 4, second paragraph of the Companies Act. The Board of Directors has the right before a shareholders meeting to decide that shareholders shall be able to exercise their voting rights by regular mail before the shareholders meeting.

The Board of Directors may collect proxies in accordance with the procedure described in Chapter 7, section 4, second paragraph of the Companies Act. The Board of Directors has the right before a shareholders meeting to decide that shareholders shall be able to exercise their voting rights by regular mail before the shareholders meeting.

                                    Persons who are not shareholders of the company shall, in accordance with terms stipulated by the Board of Directors, be entitled to attend or in some other manner monitor the proceedings of the General Meetings of Shareholders.

Other information 

For a valid resolution under the agenda item 17 a shareholder majority of two-thirds of the votes cast and the shares represented at the AGM is required. For all other agenda items above except elections, a shareholder majority of half of the votes cast at the AGM is required. For elections, the person(s) receiving the highest number of votes is elected.

Information on the proposed Board of Directors of Husqvarna AB as well as the proposed external auditor and the Nomination Committee’s Explanatory Statement etc. are available on the Company’s website, www.husqvarnagroup.com. The Annual Report and the Audit Report as well as the Auditors report on the guidelines adopted regarding remuneration are presented by being available at the Company and on the Company’s website, www.husqvarnagroup.com. They will, on request, be sent to shareholders at the address provided. The share register will be available at Husqvarna AB, Regeringsgatan 28, SE-111 53 Stockholm, Sweden.

For information on how your personal data is processed, see

https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf

Stockholm in March 2021
Husqvarna AB (publ)
THE BOARD OF DIRECTORS

For more information please contact:

Johan Andersson, Director, Corporate Communications and Investor Relations, 
+46 702 100 451 or [email protected]  

Husqvarna Group

Husqvarna Group is a global leading producer of outdoor power products and innovative solutions for forest, park and garden care. Products include chainsaws, trimmers, robotic lawn mowers and ride-on lawn mowers. The Group is also the European leader in garden watering products and a global leader in cutting equipment and diamond tools for the construction and stone industries. The Group’s products and solutions are sold under brands including Husqvarna, Gardena, McCulloch, Flymo, Zenoah and Diamant Boart via dealers and retailers to consumers and professionals in more than 100 countries. Net sales in 2020 amounted to SEK 42bn and the Group has around 12,400 employees in 40 countries.

1 Corresponding to the average closing price of Husqvarna’s B-share at Nasdaq Stockholm during December 2020, January 2021 and February 2021.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/husqvarna-ab/r/notice-of-annual-general-meeting-of-husqvarna-ab–publ-,c3304378

The following files are available for download:

Cision View original content:http://www.prnewswire.com/news-releases/notice-of-annual-general-meeting-of-husqvarna-ab-publ-301245293.html

SOURCE Husqvarna AB

Director/PDMR shareholding

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES IN ACCORDANCE WITH THE REQUIREMENTS OF THE EU AND UK MARKET ABUSE REGIMES

March 11, 2021

Royal Dutch Shell plc (the “Company”) announces that on February 12, 2021, Bram Schot, a Person Discharging Managerial Responsibilities (“PDMR”) has carried out the following transactions:

  • purchased 2,500 certificates Royal Dutch Shell A Turbo Long 8,2 BNP Paribas Markets (ISIN: NL0009558519). These certificates are cash settlement instruments the value of which is linked to the share price of the Company’s A ordinary shares with a nominal value of €0.07 each (“RDSA Shares”).  In this case, the ratio of the turbo is 1:1 and accordingly 2,500 certificates represent 2,500 RDS A shares. As at March 10, 2021, the leverage is 1.69 but fluctuates depending on the share price. If the share price increases, the leverage will decrease. The finance level is 7.57 and the stop loss level is 8.2. The finance level is adjusted on the 15th of every month. Finance costs are 1.44% on an annual basis;
  • purchased 50 Leonteq Express Euro Denominated Certificates on ING, Royal Dutch Shell, Unilever (ISIN: CH0470808913), with a nominal value of €1,000 each. These certificates are cash settlement instruments of which payment of a conditional coupon depends for 1/3 on the development of the price of the RDSA A Shares on Euronext Amsterdam and, as such, is a financial instrument linked to the RDSA A Shares.
1. Details of the person discharging managerial responsibilities/person closely associated
First Name(s) Bram
Last Name(s) Schot
2. Reason for the notification
Position/status Non-executive Director
Initial notification/amendments Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
Full name of the entity Royal Dutch Shell plc
Legal Entity Identifier code 21380068P1DRHMJ8KU70
4. Details of the transaction(s) section to be repeated for (i) each type of instrument, (ii) each type of transaction, (iii) each date, (iv) each place where transactions have been conducted
Description of the financial instrument Certificates Royal Dutch Shell A Turbo Long 8,2 BNP Paribas Markets; a financial instrument linked to RDSA A Shares
Identification Code NL0009558519
Nature of the transaction Purchase of Certificates Royal Dutch Shell A Turbo Long 8,2 BNP Paribas Markets (ISIN: NL0009558519).
Currency EUR
Price €7.69
Volume 2,500
Total €19,225
Aggregated information

 

Volume
Price
Total

 

2,500
€7.69
€19,225

 

Date of transaction February 12, 2021
Place of transaction Euronext Amsterdam

4. Details of the transaction(s) section to be repeated for (i) each type of instrument, (ii) each type of transaction, (iii) each date, (iv) each place where transactions have been conducted
Description of the financial instrument Leonteq Express Euro Denominated Certificates on ING, Royal Dutch Shell, Unilever with a nominal value of €1,000 each; a financial instrument linked to RDSA A Shares
Identification Code CH0470808913
Nature of the transaction Purchase of Leonteq Express Euro Denominated Certificates on ING, Royal Dutch Shell, Unilever (ISIN: CH0470808913), with a nominal value of €1,000 each.
Currency EUR
Price €715  
Volume 50 (with a nominal value of €1,000 each)
Total €35,750
Aggregated information

 

Volume
Price
Total

 

50 (with a nominal value of €1,000 each)
€715  
€35,750

Date of transaction February 12, 2021
Place of transaction Outside of trading venue

Notes to editor:

With a turbo long, there is a finance-level and a stop loss-level. If the underlying share price drops below the stop loss-level, the turbo long is terminated. The investor then receives the value of the difference between the finance-level and the level on which the counterparty, in this case BNP Paribas, can close the turbo. Take for example a turbo with a stop loss-level of 10 and a finance-level of 8. When the underlying share price drops below 10, which is the stop loss-level, the buyer will still receive the amount 10-8=2. However, when the shareprice would suddenly drop to 8 or below, the buyer will receive nothing and the total investment is lost. In most cases however, the turbo would be terminated at the stop loss-level, and the buyer receives the amount of the difference between the finance-level and the stop loss-level. The actual amount will be determined by BNP.

Anthony Clarke
Deputy Company Secretary

ENQUIRIES

Shell Media Relations
International, UK, European Press: +44 20 7934 5550



BioInvent presents proof-of-concept data on anti-FcyRIIB antibody BI-1607 at AACR Annual Meeting 2021

– BI-1607 designed to boost efficacy and overcome patients’ resistance to clinically validated antibody therapy

PR Newswire

LUND, Sweden, March 11, 2021 /PRNewswire/ — BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), today announces the publication of proof-of-concept data on a novel, fully human FcγRIIB-blocking antibody, BI-1607, at the American Association for Cancer Research (AACR) Annual Meeting 2021, being held virtually April 10-15 and May 17-21.

“The data on BI-1607 are very exciting and provide proof-of-concept of its ability to enhance anti-cancer immunity, illustrated by its ability to boost activity and overcome resistance to CTLA-4-based therapy,” said Martin Welschof, CEO of BioInvent. “We are looking forward to advancing BI-1607 into clinical development and expect to submit a clinical trial application during H2 2021. It will be BioInvent’s fourth drug candidate in clinical development, further demonstrating the strength and productivity of our technology platform.”

Understanding mechanisms and overcoming resistance to distinct classes of antibody drugs has the potential to further improve cancer outcomes, explains the AACR abstract, entitled “A novel FcγRIIB-blocking antibody to enhance FcγR-dependent antitumor immunity“. BI-1607 has a novel mechanism-of-action and is designed to enhance FcγR-dependent antitumor immunity. The abstract outlines how BI-1607 enhances the therapeutic activity of anti-CTLA-4 in responsive (MC38) or resistant (CT26) experimental disease models (syngeneic immune competent) and that a triple combination – of BI-1607, anti-PD-1 and low dose anti-CTLA-4 – significantly enhanced survival in a B16 tumor model not responsive to checkpoint blockade. For further information and access to the full abstract, visit https://www.abstractsonline.com/pp8/#!/9325/presentation/2743.

BioInvent’s lead compound BI-1206, evaluated in two separate Phase I trials for hematological or solid tumors, is one of three ongoing drug candidates in clinical development. The company initiated a Phase I/IIa trial of anti-TNFR2 antibody BI-1808 in January 2021 and a Phase l/lla trial of the novel oncolytic vaccinia virus BT-001, together with partner Transgene, in March 2021.

About BioInvent

BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase l/ll trials for the treatment of hematological cancer and solid tumors, respectively. The Company’s validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering.

The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company’s fully integrated manufacturing unit. More information is available at www.bioinvent.com.For further information, please contact:

Cecilia Hofvander                                     
+46 (0)46 286 85 50                                  
[email protected]              

 Mary-Ann Chang, LifeSci Advisors
 +44 7483 284853
[email protected] 

BioInvent International AB (publ)

Co. Reg. No.: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 62 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com

The information was submitted for publication, through the agency of the contact persons set out above, at 8:30 a.m. CET on March 11, 2021.

The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bioinvent/r/bioinvent-presents-proof-of-concept-data-on-anti-fcyriib-antibody-bi-1607-at-aacr-annual-meeting-202,c3303983

The following files are available for download:

https://mb.cision.com/Main/583/3303983/1384979.pdf

BioInvent presents proof-of-concept data on anti-FcyRIIB antibody BI-1607 at AACR Annual Meeting 2021

 

Cision View original content:http://www.prnewswire.com/news-releases/bioinvent-presents-proof-of-concept-data-on-anti-fcyriib-antibody-bi-1607-at-aacr-annual-meeting-2021-301245281.html

SOURCE BioInvent

Press Release for Early Warning Report Regarding Rubicon Organics Inc.

VANCOUVER, British Columbia, March 11, 2021 (GLOBE NEWSWIRE) — Eric Savics, of 505-744 West Hastings Street, Vancouver, BC, V6C 1A5, today announced that between December 17, 2020, the date of Mr. Savics’ previously filed Early Warning Report, and March 9, 2021, Mr. Savics made a series of purchases and sales of common shares (“Common Shares”) of Rubicon Organics Inc. (“Rubicon”), a company with a head office at 505-744 West Hastings Street, Vancouver, BC, V6C 1A5, which resulted in Mr. Savics realizing a net gain of 104,800 Common Shares. During this period Rubicon issued Common Shares from treasury pursuant to a bought deal public offering which resulted in a dilutive effect on Mr. Savics’ security holdings of Rubicon. The purchases and sales of Common Shares occurred through the facilities of the TSX Venture Exchange at the prevailing price of the Common Shares at the time of each purchase or sale.

As of December 17, 2020, the date of Mr. Savics’ previously filed Early Warning Report, Mr. Savics owned, directly or indirectly, or exercised control or direction over 9,593,189 Common Shares, 100,000 stock options (“Options”) each entitling the holder to purchase one Common Share, and 537,275 warrants (“Warrants”) each entitling the holder to purchase one Common Share. The 9,593,189 Common Shares represented approximately 19.76% of the total number of issued and outstanding Common Shares as of December 17, 2020. If all of his Options and Warrants were exercised, Mr. Savics would have owned, directly or indirectly, or exercised control or direction over, approximately 20.80% of the total number of issued and outstanding Common Shares on a partially diluted basis as of December 17, 2020.

As of March 9, 2021, Mr. Savics now owns, directly or indirectly, or exercises control or direction over, 9,697,989 Common Shares, 100,000 Options, and 537,275 Warrants. The 9,697,989 Common Shares represent approximately 17.48% of the total number of issued and outstanding Common Shares, resulting in a 2.28% change to Mr. Savics’ Common Share holdings. If all of his Options and Warrants were exercised, Mr. Savics would own, directly or indirectly, or exercise control or direction over, approximately 18.42% of the total number of issued and outstanding Common Shares, resulting in a 2.38% change to Mr. Savics’ Common Share holdings on a partially diluted basis as of March 9, 2021.

Mr. Savics’ disposition was made for investment management purposes. In accordance with applicable securities laws, Mr. Savics may, from time to time and at any time, acquire additional shares and/or other equity, debt or other securities or instruments (collectively, “Securities”) of Rubicon in the open market or otherwise, and reserves the right to dispose of any or all of his Securities in the open market or otherwise at any time and from time to time, and to engage in similar transactions with respect to the Securities, the whole depending on market conditions, the business and prospects of Rubicon and other relevant factors.

For more information, or to obtain a copy of the subject early warning report, please contact:

Margaret Brodie
Chief Financial Officer
Phone: 1-437-929-1964
Email: [email protected]



Advantest Named Preferred Supplier by Elmos Semiconductor

T2000 Platform Selected as Test Solution for Elmos’ Next-Generation ICs Used in Automotive Applications

TOKYO, March 11, 2021 (GLOBE NEWSWIRE) — Leading semiconductor test equipment supplier Advantest Corporation (TSE: 6857) has been named preferred supplier for its T2000 test platform by German chipmaker Elmos Semiconductor SE, a leading mixed-signal semiconductor manufacturer in the automotive industry. The scalable T2000 platform provides a reliable test solution for electronic devices used throughout automotive and industrial applications, including next-generation electronic vehicles.

“With this agreement, we strengthen our partnership and continue to grow our market share in the evolving automotive segment,” said Michael Stichlmair, managing director at Advantest Europe GmbH.

Advantest’s new supplier status means that its T2000 platform has become the preferred test solution for Elmos’ highly innovative automotive ICs. T2000 systems are already installed and in production at Elmos’ facilities.

“We highly value Advantest as a total test solutions provider for our end-to-end needs, from engineering through volume production,” said Guido Meyer, chief operating officer at Elmos Semiconductor SE. “They have demonstrated their partnership commitment over the years by providing us with leading-edge equipment as well as excellent service and dedicated team support.”

After extensive evaluation, Elmos selected the T2000 based on its ability to cost-efficiently handle the growing variety of next-generation automotive semiconductors in its portfolio. High-density, multifunctional instruments allow the system to perform both wafer-level and final testing. In addition, the tester’s high productivity and engineering efficiency has been shown to achieve the fastest time to market for a wide range of devices.

A proven tool for reducing development times for new IC designs, the flexible T2000 test platform has a modular architecture that helps users to adapt quickly to shifting market needs. For automotive device testing based on the integrated power solution (IPS), the enhanced MMXHE (multifunction mixed high voltage) and MFHPE (multifunction floating high power) modules enable massively parallel, high-performance testing by leveraging Advantest’s innovative multifunctional pin design, which allows unprecedented flexibility in assigning test resources to any pin.

For more information on the T2000 platform, visit https://www.advantest.com/products/ic-test-systems/t2000.

About Elmos Semiconductor SE

Elmos develops, produces and markets semiconductors, primarily for use in the automotive industry. Its components communicate, measure, regulate and control safety, comfort, powertrain and network functions. For over 30 years, Elmos innovations have been bringing new functions to life and making mobility worldwide safer, more comfortable and more energy efficient. With its solutions, Elmos is already the worldwide #1 in applications with great future potential, such as ultrasonic distance measurement, ambient light and intuitive human-machine interfaces (HMI). For more information, visit www.elmos.com.

About Advantest Corporation

Advantest (TSE: 6857) is the leading manufacturer of automatic test and measurement equipment used in the design and production of semiconductors for applications including 5G communications, the Internet of Things (IoT), autonomous vehicles, artificial intelligence (AI), machine learning, smart medical devices and more. Its leading-edge systems and products are integrated into the most advanced semiconductor production lines in the world. The company also conducts R&D to address emerging testing challenges and applications, produces multi-vision metrology scanning electron microscopes essential to photomask manufacturing, and offers groundbreaking 3D imaging and analysis tools. Founded in Tokyo in 1954, Advantest is a global company with facilities around the world and an international commitment to sustainable practices and social responsibility. More information is available at www.advantest.com.

ADVANTEST CORPORATION 
3061 Zanker Road
San Jose, CA 95134, USA
Tish Kelly-Mick
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0693f8ce-578e-4d10-96e1-a00352f36c64



SHAREHOLDER ALERT: WeissLaw LLP Investigates Talend S.A.

PR Newswire

NEW YORK, March 11, 2021 /PRNewswire/ — WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Talend S.A. (“Talend” or the “Company”) (NASDAQ: TLND) in connection with the proposed acquisition of the Company by Thoma Bravo, L.P., a private equity firm focused on the software and technology-enabled services sectors.  The transaction is structured as an all-cash tender offer in which the Company’s shareholders will receive $66.00 for each ordinary share of Talend and American Depositary Share that they hold.   


If you own Talend shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:


https://www.weisslawllp.com/TLND/


Or please contact:



Joshua Rubin, Esq.

WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771
[email protected]

WeissLaw LLP is investigating whether Talend’s board acted in the best interest of Talend’s public shareholders in agreeing to the proposed transaction, whether the $66.00 offer price adequately compensates Talend’s shareholders, and whether all information regarding the process undertaken by the board and the valuation of the transaction will be fully and fairly disclosed to Talend’s public shareholders.  Notably, at least one analyst has set a price target for the Company of $72.00, $6.00 above the per-share offer price.

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at [email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-talend-sa-301245233.html

SOURCE WeissLaw LLP

DouYu International Holdings Limited to Report Fourth Quarter and Full Year 2020 Financial Results on March 23, 2021

PR Newswire

WUHAN, China, March 11, 2021 /PRNewswire/ — DouYu International Holdings Limited (“DouYu” or the “Company”) (Nasdaq: DOYU), a leading game-centric live streaming platform in China and a pioneer in the eSports value chain, today announced that it plans to release its unaudited financial results for the fourth quarter and full year of 2020 before the U.S. market opens on Tuesday, March 23, 2021. The earnings release will be available on the Company’s investor relations website at http://ir.douyu.com/.

DouYu’s management will hold a conference call on Tuesday, March 23, 2021 at 8:00 A.M. Eastern Time or 8:00 P.M. Beijing Time to discuss the financial results. Listeners may access the call by dialing the following numbers:

 

International:   

1-412-317-6061

United States Toll Free: 

1-888-317-6003

Mainland China Toll Free: 

4001-206115

Hong Kong Toll Free: 

800-963976

Singapore Toll Free: 

800-120-5863

Conference ID: 

3971814

 

The replay will be accessible through March 30, 2021 by dialing the following numbers:

 

International: 

1-412-317-0088

United States Toll Free:

1-877-344-7529

Access Code: 


10153048

 

A live and archived webcast of the conference call will also be available at the Company’s investor relations website at http://ir.douyu.com/.

About DouYu International Holdings Limited

Headquartered in Wuhan, China, DouYu International Holdings Limited (Nasdaq: DOYU) is a leading game-centric live streaming platform in China and a pioneer in the eSports value chain. DouYu operates its platform on both PC and mobile apps, through which users can enjoy immersive and interactive games and entertainment live streaming. DouYu’s platform brings together a deep pool of top live streamers. By providing a sustainable streamer development system built on advanced technology infrastructure and capabilities, DouYu helps ensure a consistent supply of quality content. Through collaborations with a variety of participants across the eSports value chain, the Company has gained coveted access to a wide variety of premium eSports content, which further attracts viewers and enhances user experience. For more information, please see http://ir.douyu.com/.

Investor Relations Contact

Mao Mao

DouYu International Holdings Limited
Email: [email protected]
Phone: +1 (646) 224-6934

Xinran Rao

ICR, Inc.
Email: [email protected]
Phone: +1 (646) 224-6934

Media Relations Contact

Iris Ding

DouYu International Holdings Limited
Email: [email protected]
Phone: +1 (646) 308-1475

Edmond Lococo

ICR, Inc.
Email: [email protected]
Phone: +1 (646) 308-1475

Cision View original content:http://www.prnewswire.com/news-releases/douyu-international-holdings-limited-to-report-fourth-quarter-and-full-year-2020-financial-results-on-march-23-2021-301245226.html

SOURCE DouYu International Holdings Limited